Biomarin Pharmaceutical Inc. - Registered Shares

NASDAQ:BMRN   3:59:45 PM EDT
76.88
-0.65 (-0.84%)
Products

Biomarin Receives FDA Approval Of Label Expansion To Allow Palynziq Injection For Treatment Of Adults With PKU

Published: 10/07/2020 12:47 GMT
Biomarin Pharmaceutical Inc (BMRN) - Biomarin, Pioneer in Rare Disease Treatments for Phenylketonuria (pku), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 Mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults With Pku.